MetrionAIIntelligence

Sign in Register

Home Watchlist Market News High Impact News Market Movers Screener Portfolio Calculators Heatmap Compare Calendars Crypto Forex Macro Maps

Research Tools

Financial Analysis Analyst Estimates Insider Trading Market Guide Trading Ideas Charts

Financial Analysis

Highlights Income Statement Balance Sheet Cash Flow Multiples Profitability

Loading market dashboard

My Watchlist

Sign in to track securities

Create an account to keep a persistent watchlist.

Home High Impact News Market Movers

Loading news article

Back to markets

zacks.com/May 25, 2026 at 12:40 PMAZN

AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors

AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.

Open original source